Future Revascularization Evaluation in patients with Diabetes mellitus
This is a multicenter, two-arm, open label prospective randomized trial. The objective of this trial is to evaluate whether percutaneous coronary intervention (PCI) with drug-eluting stenting (DES) is more or less effective than the existing standard of care, coronary artery bypass surgery (CABG).
Winthrop-University Hospital - Division of Cardiology is one of the participating site to enroll subjects with diabetes mellitus (Type 1 or Type 2) with angiographically confirmed multivessel coronary artery disease (CAD) and morphology amenable to either PCI or CABG, with indication for revascuralization based upon symptoms or angina and/or objective evidence of myocardial ischemia. Eligible subjects are randomized to receive either CABG or multivessel stenting using drug-eluting stents, and followed at 30 days, 1 year and then annually for up to 6.75 years.
Eligibility Criteria: - Age 18 years or older - Diabetes Mellitus (Type 1 or Type 2) undergoing treatment - Angiographically confirmed multivessel CAD lesions in at least two major coronary arteries
Srihari Naidu, MD
Division of Cardiology
For more information please call Research Coordinator at 516-663-8692.